SCHEMBL20649166

SCHEMBL20649166

CC(C)(C)OC(=O)Nc1nc(CC(=O)N2CCC(NC(=O)OC(C)(C)C)CC2)cs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.46
F2 P00734 4/20 0.44
F10 P00742 4/20 0.44
NAMPT P43490 1/20 0.41
PARP1 P09874 2/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
DRD2 P14416 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HSD17B1 P14061 1/20 0.39
HSD11B1 P28845 1/20 0.39
HSD17B2 P37059 1/20 0.39
KCNA3 P22001 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21875645 0.94 F2 (0.43) SIRT1F2F10NAMPTPARP1
SCHEMBL19820646 0.85 F2 (0.53) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL30932919 0.85 HSD11B1 (0.52) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL20649325 0.84 F2 (0.52) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL20649327 0.84 SIRT1 (0.46) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL28391886 0.83 F2 (0.55) SIRT1F2F10HSD17B1HSD11B1
SCHEMBL3537265 0.82 F10 (0.66) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL28396135 0.82 F2 (0.50) SIRT1F2F10SMN1; SMN2HSD17B1
SCHEMBL28397380 0.81 F2 (0.47) SIRT1F2F10
SCHEMBL3538448 0.81 F2 (0.63) SIRT1F2F10SMN1; SMN2HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110997678-B Pyrazoloquinazoline derivatives as choline kinase inhibitors 内尔维亚诺医疗科学公司 2023-02-21 CN disclosed
US-11117901-B2 Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-09-14 US disclosed
US-20200131188-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-04-30 US disclosed
WO-2019011715-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131188-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS CHKA, CHKB, NADK SIRT1 450/4885F2 4175/4885F10 4714/4885
US-11117901-B2 Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors CHKA, CHKB, NADK SIRT1 648/4885F2 3893/4885F10 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.